摘要
肢端肥大症是一种慢性进展性内分泌疾病,95%以上由垂体生长激素腺瘤所致。这种腺瘤可分泌过量的生长激素并导致肝脏分泌过量的胰岛素样生长因子-1,过量的生长激素和胰岛素样生长因子-1会共同引起患者容貌改变和心血管、代谢、骨骼等诸多并发症。肢端肥大症的治疗目标是将生长激素和胰岛素样生长因子-1的水平降至正常,切除腺瘤,控制并发症。药物是治疗肢端肥大症的重要手段之一。本文概要介绍目前临床治疗肢端肥大症的常用药物,以及现尚处于后期临床试验阶段、未来可能上市的新药。
Acromegaly is a chronic,progressive endocrine disorder that is primarily caused by pituitary growth hormone adenoma.This condition results in excessive synthesis and secretion of growth hormone(GH),which subsequently leads to the increased release of insulin-like growth factor-1(IGF-1)from the liver.The overproduction of GH and IGF-1 causes significant alterations in appearance,as well as comorbidities such as cardiovascular,metabolic,and skeletal issues.The therapeutic goals for acromegaly include normalizing blood levels of GH and IGF-1 through medication,resecting tumor by surgery and management of comorbidities.Medical therapy remains a critical component in the treatment of acromegaly.This article summarizes the current available drugs for its treatment and the potential drugs that is being investigated in late-stage clinical trials and may be marketed in the future.
作者
俞一飞
李益明
张朝云
YU Yifei;LI Yiming;ZHANG Zhaoyun(Department of Endocrinology and Metabolism,Huashan Hospital,Fudan University,Shanghai 200040,China)
出处
《上海医药》
2025年第6期3-6,22,共5页
Shanghai Medical & Pharmaceutical Journal
基金
国家科技创新2030--“癌症、心脑血管、呼吸和代谢性疾病防治研究”重大项目(2023ZD0506800、2023ZD0506802)。
